Evidence for the DNA binding and adduct formation of estrone and 17β- estradiol after dimethyldioxirane activation

Chemico-Biological Interactions

Volumn 110, Issue 3, 1998, Pages 173-187

  Yu, Fu Li ^a   Wang, Mian Ying ^a   Li, Dong Hui ^b   Bender, Wanda ^a   Wei Yun Zheng, ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

17 Estradiol; 32P postlabeling; Dimethyldioxirane epoxidation; DNA binding; Estrone

Indexed keywords

ESTRADIOL; ESTRADIOL RECEPTOR; ESTRONE;

ARTICLE; BREAST CANCER; CANCER THERAPY; CARCINOGENESIS; DATA ANALYSIS; DNA ADDUCT; DNA BINDING; EPOXIDATION; HORMONAL THERAPY; HORMONE SUBSTITUTION; HYPOTHESIS; RNA SYNTHESIS; UTERUS CANCER;

ANIMALS; CARCINOGENS; CATTLE; DNA; DNA ADDUCTS; DNA-DIRECTED RNA POLYMERASES; EPOXY COMPOUNDS; ESTRADIOL; ESTRONE; KINETICS; OXIDATION-REDUCTION; PHOSPHORUS RADIOISOTOPES; POLYDEOXYRIBONUCLEOTIDES; RADIOISOTOPE DILUTION TECHNIQUE; RATS; RNA; TEMPLATES, GENETIC; TRANSCRIPTION, GENETIC;

EID: 0032478594     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(98)00007-6     Document Type: Article

References (44)

1. Parker S.L., Tong T., Bolden S., Wingo P.A. Cancer statistics, 1997. CA Cancer J. Clin. 47:1997;5-27.
2. Mack T.M., Pike M.C., Henderson B.E., Pfeffer R.l., Gerkins V.R., Arthur M., Brown S.E. Estrogens and endometrial cancer in a retirement community. New Engl. J. Med. 294:1976;1262-1267.
3. Mcgonigle K.F., Karlan B.Y., Barbuto D.A., Leuchter R.S., Lagasse L.D., Judd H.L. Development of endometrial cancer in women on estrogen and progestin hormone replacement therapy. Gynecol. Oncol. 55:1994;126-132.
4. Grady D., Gebretsakid T., Kerlikowske K., Ernster V., Petitti D. Hormone replacement therapy and endometrial cancer: a meta-analysis. Obstet. Gynecol. 85:1995;304-313.
5. Harris R.E., Namboodiri K.K., Wynder E.L. Breast cancer risk: effects of estrogen replacement therapy and body mass. J. Natl. Cancer Inst. 84:1992;1575-1582.
6. J.M. Pike, L. Bernstein, D. Spicer, Exogenous hormones and breast cancer risk, in: J. Neiderhuber (Ed.), Current Therapy in Oncology, B.C. Decker, St. Louis, 1993, pp. 292-302.
7. Steinberg K., smith S., Thacker S., Stroup D. Breast-cancer risk and duration of estrogen use: the role of study design in meta-analysis. Epidemiology. 5:1994;415-421.
8. Toniolo P.G., Levitz M., Zeleniuch-Jacquotte A., Banerjee S., Koenig K.L., Shore R.E., Strax P., Pasternack B.S. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J. Natl. Cancer Inst. 87:1995;190-197.
9. Colditz G.A., Hankinson S.E., Hunter D.J., Willett W.C., Manson J.E., Stampfer M.J., Hennekens C., Rosner B., Speizer F.E. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New Engl. J. Med. 332:1995;1589-1593.
10. Venn A., Watson L., Lumley J., Giles G., King C., Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilization. Lancet. 346:1995;995-1000.
11. Wanless I.R., Medline A. The role of estrogens as promoters of hepatic neoplasia. Lab. Invest. 46:1982;313-320.
12. Li J.J., Li S.A. Estrogen carcinogenesis in hamster tissues: a critical review. Endocr. Rev. 11:1990;524-531.
13. Dragan Y.P., Xu Y.D., Pitot H.C. Tumor promotion as a target for estrogen/antiestrogen effects in rat hepatocarcinogenesis. Prev. Med. 20:1991;15-26.
14. Weisburger E.K. Metabolism and activation of chemical carcinogens. Mol. Cell. Biochem. 32:1980;95-104.
15. Miller E.C., Miller J.A. Searches for ultimate chemical carcinogens and their reactions with cellular macromolecules. Cancer. 47:1981;2327-2345.
16. Farber E. Cellular biochemistry of the stepwise development of cancer with chemicals: G.H.A. Clowes memorial lecture. Cancer Res. 44:1984;5463-5474.
17. Harris C.C. Chemical and physical carcinogenesis: advances and perspective for the 1990s. Cancer Res. Suppl. 51:1991;5023s-5044s.
18. Hemminki K. DNA adducts, mutations and cancer. Carcinogenesis. 14:1993;2007-2012.
19. Dipple A. DNA adducts of chemical carcinogens. Carcinogenesis. 16:1995;437-441.
20. 1 to the transcriptionally active regions of rat liver nucleolar chromatin in vivo and in vitro. Carcinogenesis. 4:1983;889-893.
21. 1 inhibition of rat liver nuclear RNA polymerase II activity in vivo. Carcinogenesis. 7:1986;253-257.
22. 1 binding to single- and double-stranded DNAs. Carcinogenesis. 11:1990;475-478.
23. 1 on cytosine and/or hypoxanthine containing DNAs. Mol. Cell. Biochem. 103:1991;1-8.
24. 1-8,9-epoxide. Carcinogenesis. 15:1994;1737-1741.
25. be-8,9-epoxide-DNA adducts on transcription of a SupF gene fragment. Cancer Lett. 109:1996;77-83.
26. Park K.K., Surh Y.J., Stewart B.C., Miller J.A. Synthesis and properties of vinyl-carbamate epoxide, a possible ultimate electrophilic and carcinogenic metabolise of vinyl carbamate and ethyl carbamate. Biochem. Biophys. Res. Commun. 169:1990;1094-1098.
27. Adam W., Chan Y.Y., Cremer D., Gauss J., Scheutzow D., Schindler M. Spectral and chemical properties of dimethyldioxirane as determined by experiment and ab initio calculations. J. Org. Chem. 52:1987;2800-2803.
28. Baertschi S.W., Raney K.D., Stone M.P., Harris T.M. Preparation of the 8,9-epoxide of the mycotoxin aflatoxin Be: the ultimate carcinogenic species. J. Am. Chem. Soc. 110:1988;7929-7931.
29. Park K.K., Sohn Y., Liem A., Kim H.J., Stewart B.C., Miller J.A. The electrophilic and tumorigenic activities of phenyl and 4-nitrophenyl vinyl ethers and their epoxide metabolites. Carcinogenesis. 18:1997;431-437.
30. Yu F.L., Bender W. Activation of 17β-estradiol and estrone by dimethyldioxirane and inhibition of rat liver nuclear and nucleolar RNA synthesis in vitro. Carcinogenesis. 17:1996;1957-1961.
31. 1: a new metabolite. Chem. Res. Toxicol. 5:1992;333-335.
32. 1: mechanistic studies. J. Am. Chem. Soc. 116:1994;1603-1609.
33. Yu F.L. Two functional states of the RNA polymerases in rat hepatic nuclear and nucleolar fractions. Nature. 251:1974;344-346.
34. Yu F.L. An improved method for the quantitative isolation of rat liver nuclear RNA polymerases. Biochim. Biophys. Acta. 395:1975;329-336.
35. 32P-postlabeling test for structurally diverse DNA adducts. Carcinogenesis. 7:1986;1543-1551.
36. Li D., Randerath K. Association between diet and age-related DNA modifications (I-compounds) in rat liver and kidney. Cancer Res. 50:1990;3991-3996.
37. Wang M.Y., Liehr J.G. Lipid hydroperoxide-induced endogenous DNA adducts in hamsters: possible mechanism of lipid hydroperoxide-mediated carcinogenesis. Arch. Biochem. Biophys. 316:1995;38-46.
38. 1 to the chromatin components and the inhibition of RNA synthesis. Carcinogenesis. 9:1988;527-532.
39. 1 to rat liver nucleolar proteins and its effect on DNA-dependent RNA synthesis. Carcinogenesis. 9:1988;533-540.
40. T.L. Dao, The role of ovarian steriod hormones in mammary carcinogenesis, in: M.C. Pike, P.K. Siiteri and C.W. Welsch (Eds.), Hormones and Breast Cancer (Banbury Report No. 8), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1991, pp. 281-295.
41. Kirkman H. Estrogen-induced tumors of the kidney in the Syrian Hamster. Natl. Cancer Inst. Monogr. 1:1959;1-58.
42. Leihr J.G., Roy D. Free radical generation by redox cycling of estrogens. Free Radic. Biol. Med. 8:1990;415-423.
43. Yager J.D., Lelhr J.G. Molecular mechanisms of estrogen carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 36:1996;203-232.
44. W.F. Busby and G.N. Wogan, Aflatoxins, in: C.E. Searle (Ed.), Chemical Carcinogens, 2nd ed., ACS Monograph 182, American Chemical Society, Washington, DC, 1984, pp. 945-1136.